Amarin Corp Plc (AMRN)

[retinadoc]

I think Mitigate will read out positive. Like Reduce-it we have several leading indicators. Cardio-Link 9, and a recent paper on success in several long Covid patients. COVID is a vascular disease and unquestionably has a significant associated coagulopathy. (remember COVID toes?). It is also not in dispute that survivors are at increased risk of a major vascular event post COVID for up to six months.

Vascepa is a mild blood thinner and that alone could drive a positive result. Add in its endothelial cell protection and I think you will see the Reduce-it results replicated or exceeded.

So then what happens? Does STAT news, Nissen, Krumholz finally fall on their swords? Somehow I doubt it. Will Vascepa become SOC for post-COVID? Does BP wake up and now take notice? Sarissa gets into the game?

Mitigate is a seismic event that like Reduce-it may radically change Amarin's fortunes.

One can hope that Vascepa's real efficacy finally wins the day.